Kolexia
Gac-Besnard Anne-Claire Hématologie
Gac-Besnard Anne-Claire
Hématologie
Hôpital Côte de Nacre
Caen, France
91 Activités
322 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Maladie de Hodgkin Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Lymphome B diffus à grandes cellules Lymphome B Seconde tumeur primitive Lymphome malin non hodgkinien

Collaborateurs

Voir plus
Chantepie Sylvain
Chantepie Sylvain
Hôpital Côte de Nacre, Caen, France
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France
Reman Oumedaly
Reman Oumedaly
CHU Caen, Caen, France
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France

Industries

Voir plus
Abbvie
3 collaboration(s)
Dernière en 2023
Janssen
3 collaboration(s)
Dernière en 2023
Incyte
2 collaboration(s)
Dernière en 2023
Celgene
2 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
Agricultural exposures and DNA damage in PBMC of female farmers measured using the alkaline comet assay.
International archives of occupational and environmental health   02 mars 2024
Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for untreated older Hodgkin lymphoma patients.
Blood   18 novembre 2023
Interleukin 10 (IL10) and IL15 Significantly Decreased in Chronic Myeloid Leukemia Patients Presenting with Tyrosine Kinase Inhibitor (TKI) Withdrawal Syndrome (TWS). Results from the Prospective, Explorative and Multicenter « Kiwis » Study Designed for TWS. Clinicaltrial.Gov ID: NCT03996096; Study Number: 18-206
65th ASH Annual Meeting Abstracts   02 novembre 2023
Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial.
Leukemia research   18 mars 2023
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.
Haematologica   01 décembre 2022
BREACH: Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study
Essai Clinique (Millennium Pharmaceuticals)   18 août 2022
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
Leukemia & lymphoma   17 août 2022
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   22 juillet 2022
Low total gamma globulin level discovery at diffuse large B-cell lymphoma diagnosis predicts high risk of infection-related death: data from a monocentric retrospective study.
Swiss medical weekly   06 juin 2022
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   06 janvier 2022